E board review in Breast Cancer February 2008 Word from Editor

Article

E board review in Breast Cancer February 2008 Word from Editor

 

E-Board Review in Oncology:
Breast Cancer

Dear Colleague:

This month on CancerNetwork.com you will find an online review in breast cancer-an invaluable resource for you as you prepare to face the Medical Oncology Board Certification Examination. It is our aim that this review not only assist you in your preparation for the exam, but also enable you to better discern the critical issues that we all face in the treatment of breast cancer.

My colleagues Steven M. Sorscher, Cynthia X. Ma, and I have divided the 36 questions in this review (expired) into 5 sections: Reducing Risk/Increasing Survival, Adjuvant Therapy, Treatment Results, Advanced and Recurrent Disease, and Breast Cancer Subtypes. For each question, you will be given both rationales for the correct answer and explanations for why the incorrect answers are indeed incorrect. In addition, each question/answer is supported by appropriate references. For your convenience, a complete suggested reading list for the entire program is provided as well.

We hope that you find this e-review to be a key resource, both for your board preparation and toward the ultimate aim we all share: providing the highest quality of care possible for our patients, offering maximal survival and the best quality of life.

Sincerely yours,

Matthew J. Ellis, MB, BChir, PhD, FRCP
Director, Breast Cancer Program
Anheuser Busch Tenured
Associate Professor of Medicine
Washington University School of Medicine
St. Louis, Missouri

Recent Videos
With many treatments emerging in the EGFR-mutated lung cancer landscape, sequencing therapy has emerged as a key consideration for these patients.
Although a greater risk of CNS relapse may emerge with immunotherapy-based backbones, toxicities associated with chemotherapy are avoided.
Current FDA expectations may allow patients to return to their community physicians at 2 weeks after administration of anitocabtagene autoleucel.
Based on its mechanism of action, anito-cel may cause fewer instances of cytokine release syndrome and delayed toxicities vs other therapies.
2 experts are featured in this series.
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Related Content
The 6- and 12-month PFS rates were 76.4% and 68.2%, respectively, in patients with relapsed/refractory multiple myeloma who discontinued treatment with teclistamab early.

Discontinuing Teclistamab Early Yields Comparable Efficacy vs Continuous Therapy in RRMM

Caroline Seymour
December 11th 2025
Article

The 6- and 12-month PFS rates were 76.4% and 68.2%, respectively, in patients with relapsed/refractory multiple myeloma who discontinued treatment with teclistamab early.

Why Sexual and Gender Minority Care is an Oncologic Imperative

Why Sexual and Gender Minority Care is an Oncologic Imperative

Daniel C. McFarland, DO;Charles S. Kamen, PhD, MPH
December 8th 2025
Podcast

Daniel C. McFarland, DO, and Charles S. Kamen, PhD, MPH, focused on cultural humility, nonverbal data collection, and tailored resources to improve care.

Across all dose levels of axatilimab, the 46-month OS rate was the 74.1% among patients with previously treated chronic graft-vs-host disease.

Axatilimab Confers Promising Early Efficacy/Tolerability in Chronic GVHD

Jonah Feldman
December 11th 2025
Article

Across all dose levels of axatilimab, the 46-month OS rate was the 74.1% among patients with previously treated chronic graft-vs-host disease.

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

How to Manage Oligometastatic Kidney Cancer? Insights From IKCS 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
December 4th 2025
Podcast

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

The 60-month local regional recurrence-free rate was 93.2% in the MRI arm vs 95.7% in the no MRI arm among patients with newly diagnosed breast cancer.

Resecting MRI-Detected Disease Doesn’t Improve Outcomes in Early-Stage BC

Tim Cortese
December 11th 2025
Article

The 60-month local regional recurrence-free rate was 93.2% in the MRI arm vs 95.7% in the no MRI arm among patients with newly diagnosed breast cancer.

Findings from the P-RAD trial show encouraging rates of pathologic complete response among patients who received pembrolizumab plus radiotherapy.

Pembrolizumab/Radiation Improves T Cell Infiltration in Early Breast Cancer

Russ Conroy
December 11th 2025
Article

Findings from the P-RAD trial show encouraging rates of pathologic complete response among patients who received pembrolizumab plus radiotherapy.